Innate Pharma/$IPHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Ticker
$IPHA
Sector
Primary listing
Employees
163
Headquarters
Website
Innate Pharma Metrics
BasicAdvanced
$132m
-
-$0.64
0.75
-
Price and volume
Market cap
$132m
Beta
0.75
52-week high
$2.63
52-week low
$1.17
Average daily volume
29k
Financial strength
Current ratio
1.275
Quick ratio
1.144
Long term debt to equity
-63.449
Total debt to equity
-104.004
Interest coverage (TTM)
-122.75%
Profitability
EBITDA (TTM)
-62.481
Gross margin (TTM)
-384.40%
Net profit margin (TTM)
-546.11%
Operating margin (TTM)
-599.77%
Revenue per employee (TTM)
$70,320
Management effectiveness
Return on assets (TTM)
-38.85%
Return on equity (TTM)
764.21%
Valuation
Price to revenue (TTM)
12.224
Price to book
-5.18
Price to tangible book (TTM)
-5.18
Price to free cash flow (TTM)
-2.081
Free cash flow yield (TTM)
-48.05%
Free cash flow per share (TTM)
-0.692
Growth
Revenue change (TTM)
-55.25%
Earnings per share change (TTM)
-9.89%
3-year revenue growth (CAGR)
-46.15%
10-year revenue growth (CAGR)
-9.76%
3-year earnings per share growth (CAGR)
-9.07%
10-year earnings per share growth (CAGR)
15.52%
What the Analysts think about Innate Pharma
Analyst ratings (Buy, Hold, Sell) for Innate Pharma stock.
Innate Pharma Financial Performance
Revenues and expenses
Innate Pharma Earnings Performance
Company profitability
Innate Pharma News
AllArticlesVideos
Innate Pharma to Participate in the D. Boral Capital Global Conference
Business Wire·2 weeks ago
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Business Wire·2 weeks ago
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Innate Pharma stock?
Innate Pharma (IPHA) has a market cap of $132M as of May 04, 2026.
What is the P/E ratio for Innate Pharma stock?
The price to earnings (P/E) ratio for Innate Pharma (IPHA) stock is 0 as of May 04, 2026.
Does Innate Pharma stock pay dividends?
No, Innate Pharma (IPHA) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next Innate Pharma dividend payment date?
Innate Pharma (IPHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Innate Pharma?
Innate Pharma (IPHA) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.